Research Keyword: MDMA therapy

Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report

mycolabadmin

A 41-year-old woman with Long-COVID experienced severe symptoms including fatigue, depression, anxiety, headaches, and brain fog that didn’t improve with traditional treatments. She decided to try psilocybin mushrooms and MDMA with guidance from a therapist. After multiple dosing sessions over several months, she reported roughly 80-90% improvement in her symptoms and was able to return to work and resume her studies. While this single case is promising, more research is needed to determine whether these psychedelics are truly safe and effective for Long-COVID.

Read More »

Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program

mycolabadmin

Switzerland operates a unique program allowing controlled use of psychedelics (LSD, psilocybin) and MDMA to help patients with serious mental health conditions that haven’t responded to standard treatments. Since 2014, about 100 doctors have treated 700+ patients with these substances as part of therapy sessions. The program requires careful patient screening, informed consent, and outcome reporting, with patients typically receiving 2-4 treatments over 12 months. Most patients showed significant improvement in their conditions, though some experienced side effects like nausea or headaches.

Read More »
Scroll to Top